Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 6/20 | 0.65 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.65 |
| ▸ | HTR2C | P28335 | 14/20 | 0.47 |
| ▸ | HTR2B | P41595 | 14/20 | 0.47 |
| ▸ | HTR2A | P28223 | 9/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6781331 | 0.90 | MTNR1A (0.55) | MTNR1AMTNR1BHTR2CHTR2BHTR2A | |
| SCHEMBL6789183 | 0.86 | MTNR1B (0.69) | MTNR1AMTNR1BSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6786502 | 0.80 | MTNR1B (0.81) | MTNR1AMTNR1B | |
| SCHEMBL6790908 | 0.80 | MTNR1A (0.69) | MTNR1AMTNR1BHTR2CHTR2BHTR2A | |
| SCHEMBL6781325 | 0.80 | HTR2C (0.46) | MTNR1AMTNR1BHTR2CHTR2BHTR2A | |
| SCHEMBL6783477 | 0.79 | MTNR1B (1.00) | MTNR1AMTNR1B | |
| SCHEMBL6785417 | 0.79 | MTNR1A (0.60) | MTNR1AMTNR1BSLC6A4 | |
| SCHEMBL6784158 | 0.78 | MTNR1B (0.78) | MTNR1AMTNR1B | |
| SCHEMBL6782062 | 0.78 | MTNR1A (0.65) | MTNR1AMTNR1B | |
| SCHEMBL6780444 | 0.78 | MTNR1A (1.00) | MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6737431-B2 | SUCH AS N-(3-(2-METHYLBENZOXAZOL-7-YL)PROPYL)PROPANAMIDE; CIRCADIAN RHYTHM RELATED DISORDERS | BRISTOL-MYERS SQUIBB COMPANY | 2004-05-18 | — | — | US | disclosed |
| US-20030216456-A1 | Benzoxazole derivatives as novel melatonergic agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216456-A1 | Benzoxazole derivatives as novel melatonergic agents | MTNR1A, MTNR1B, MC1R | MTNR1A 1/4885MTNR1B 2/4885HTR2C 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.